MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
September 02 2009 - 7:00AM
PR Newswire (US)
- Investor Webcast to Discuss Phase 3 LEVADEX(TM) Data Presented in
Late-Breaking Session at the 14th Congress of the International
Headache Society - MOUNTAIN VIEW, Calif., Sept. 2
/PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP)
today announced that it will participate in the following events in
September: Thomas Weisel Partners Healthcare Conference 2009
Friday, September 11, at 10:20 a.m. ET in Boston 14th Congress of
the International Headache Society September 10 to 13, in
Philadelphia Late-Breaking oral platform presentation on Saturday,
September 12, at 7:35 a.m. ET Three posters can be viewed during
the conference Webcast to discuss Phase 3 LEVADEX(TM) data
presented in a late-breaking session at the 14th Congress of the
International Headache Society Monday, September 14th at 7:15 a.m.
ET Morgan Stanley Global Healthcare Conference Monday, September
14, at 1:00 p.m. ET in New York City Live webcasts of the events on
Friday, September 11 and Monday, September 14 will be available in
the Investor Relations section of MAP Pharmaceuticals' website at
http://www.mappharma.com/. A replay will also be available within
24 hours for at least seven days following each presentation. About
MAP Pharmaceuticals MAP Pharmaceuticals is dedicated to developing
and commercializing new therapies for patients suffering from
conditions that are not adequately treated by currently available
medicines. The company is developing LEVADEX orally inhaled therapy
for the potential treatment of migraine and has reported positive
results from the efficacy portion of the first Phase 3 trial of
LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline
opportunities by applying its proprietary drug particle and
inhalation technologies to enhance the therapeutic benefits of
proven drugs, while minimizing risk by capitalizing on their known
safety, efficacy and commercialization history. CONTACT: Lisa
Borland (650) 386-3122 http://www.mappharma.com/ DATASOURCE: MAP
Pharmaceuticals, Inc. CONTACT: Lisa Borland of MAP Pharmaceuticals,
Inc., +1-650-386-3122 Web Site: http://www.mappharma.com/
Copyright